NO20042288L - Kinazolinderivater som antitumormidler - Google Patents
Kinazolinderivater som antitumormidlerInfo
- Publication number
- NO20042288L NO20042288L NO20042288A NO20042288A NO20042288L NO 20042288 L NO20042288 L NO 20042288L NO 20042288 A NO20042288 A NO 20042288A NO 20042288 A NO20042288 A NO 20042288A NO 20042288 L NO20042288 L NO 20042288L
- Authority
- NO
- Norway
- Prior art keywords
- antitumor agents
- quinazoline derivatives
- quinazoline
- derivatives
- antitumor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Ceramic Engineering (AREA)
- Health & Medical Sciences (AREA)
- Manufacturing & Machinery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Structural Engineering (AREA)
- Materials Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0126433.2A GB0126433D0 (en) | 2001-11-03 | 2001-11-03 | Compounds |
PCT/GB2002/004932 WO2003040109A2 (en) | 2001-11-03 | 2002-10-31 | Quinazoline derivatives as antitumor agents |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20042288L true NO20042288L (no) | 2004-06-03 |
Family
ID=9925096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20042288A NO20042288L (no) | 2001-11-03 | 2004-06-03 | Kinazolinderivater som antitumormidler |
Country Status (25)
Country | Link |
---|---|
US (2) | US20050054662A1 (no) |
EP (1) | EP1444211B1 (no) |
JP (1) | JP2005511603A (no) |
KR (1) | KR20050042058A (no) |
CN (1) | CN1764651A (no) |
AR (1) | AR037193A1 (no) |
AT (1) | ATE421507T1 (no) |
BR (1) | BR0213843A (no) |
CA (1) | CA2465100A1 (no) |
CO (1) | CO5580775A2 (no) |
DE (1) | DE60230995D1 (no) |
ES (1) | ES2319880T3 (no) |
GB (1) | GB0126433D0 (no) |
HK (1) | HK1065801A1 (no) |
HU (1) | HUP0401994A2 (no) |
IL (1) | IL161620A0 (no) |
IS (1) | IS7241A (no) |
MX (1) | MXPA04004220A (no) |
NO (1) | NO20042288L (no) |
NZ (1) | NZ532523A (no) |
PL (1) | PL369833A1 (no) |
RU (1) | RU2004116908A (no) |
TW (1) | TW200302221A (no) |
WO (1) | WO2003040109A2 (no) |
ZA (2) | ZA200403200B (no) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030125344A1 (en) * | 2001-03-23 | 2003-07-03 | Bayer Corporation | Rho-kinase inhibitors |
US20030087919A1 (en) * | 2001-03-23 | 2003-05-08 | Bayer Corporation | Rho-kinase inhibitors |
MXPA04004219A (es) * | 2001-11-03 | 2004-09-10 | Astrazeneca Ab | Derivados de quinazolina como agentes antitumorales. |
CN101607958A (zh) * | 2002-02-01 | 2009-12-23 | 阿斯特拉曾尼卡有限公司 | 喹唑啉化合物 |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
ES2400339T3 (es) | 2002-07-15 | 2013-04-09 | Symphony Evolution, Inc. | Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer |
GB0309009D0 (en) * | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
GB0309850D0 (en) * | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
GB0321648D0 (en) * | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
DE602004022180D1 (de) * | 2003-09-16 | 2009-09-03 | Astrazeneca Ab | Chinazolinderivate |
US20080234263A1 (en) * | 2003-09-16 | 2008-09-25 | Laurent Francois Andre Hennequin | Quinazoline Derivatives |
DK1667991T3 (da) * | 2003-09-16 | 2008-08-18 | Astrazeneca Ab | Quinazolinderivater som tyrosinkinaseinhibitorer |
CN1882573A (zh) * | 2003-09-16 | 2006-12-20 | 阿斯利康(瑞典)有限公司 | 作为酪氨酸激酶抑制剂的喹唑啉衍生物 |
GB0322409D0 (en) * | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
EP2612853A1 (en) | 2003-09-26 | 2013-07-10 | Exelixis Inc. | c-Met modulators and methods of use |
DE10345875A1 (de) * | 2003-09-30 | 2005-04-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Vewendung und Verfahren zu ihrer Herstellung |
GB0326459D0 (en) * | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
TW200536851A (en) | 2004-01-23 | 2005-11-16 | Amgen Inc | Compounds and methods of use |
JP2007518823A (ja) | 2004-01-23 | 2007-07-12 | アムゲン インコーポレイテッド | キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途 |
EP1713781B1 (en) | 2004-02-03 | 2008-11-05 | AstraZeneca AB | Quinazoline derivatives |
UA85706C2 (en) | 2004-05-06 | 2009-02-25 | Уорнер-Ламберт Компани Ллси | 4-phenylaminoquinazolin-6-yl amides |
CN1993349A (zh) * | 2004-06-04 | 2007-07-04 | 阿斯利康(瑞典)有限公司 | 作为erbb受体酪氨酸激酶的喹唑啉衍生物 |
AU2005293336B2 (en) | 2004-10-12 | 2009-05-28 | Astrazeneca Ab | Quinazoline derivatives |
MX2007006230A (es) | 2004-11-30 | 2007-07-25 | Amgen Inc | Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer. |
ATE405553T1 (de) * | 2004-12-08 | 2008-09-15 | Bristol Myers Squibb Co | Heterocyclische verbindungen als inhibitoren von faktor viia |
ATE501148T1 (de) * | 2004-12-14 | 2011-03-15 | Astrazeneca Ab | Pyrazolopyrimidinverbindungen als antitumormittel |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
EP1833482A4 (en) | 2005-01-03 | 2011-02-16 | Myriad Genetics Inc | COMPOUNDS AND ITS THERAPEUTIC USE |
GB0504475D0 (en) * | 2005-03-04 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
GB0504474D0 (en) * | 2005-03-04 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
GB0508715D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
GB0508717D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
WO2007030582A2 (en) | 2005-09-09 | 2007-03-15 | Bristol-Myers Squibb Company | Acyclic ikur inhibitors |
JP2009508917A (ja) * | 2005-09-20 | 2009-03-05 | アストラゼネカ アクチボラグ | 抗癌剤としてのキナゾリン誘導体 |
EP1928861B1 (en) * | 2005-09-20 | 2010-11-17 | AstraZeneca AB | 4- (ih-indazol-5-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer |
ZA200804498B (en) | 2005-11-15 | 2009-07-29 | Array Biopharma Inc | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ERBB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
US20090029968A1 (en) * | 2005-12-02 | 2009-01-29 | Bernard Christophe Barlaam | Quinazoline derivatives used as inhibitors of erbb tyrosine kinase |
WO2007063291A1 (en) | 2005-12-02 | 2007-06-07 | Astrazeneca Ab | 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors |
US7482607B2 (en) * | 2006-02-28 | 2009-01-27 | Lawrenceville Plasma Physics, Inc. | Method and apparatus for producing x-rays, ion beams and nuclear fusion energy |
UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
AU2007261440A1 (en) * | 2006-06-22 | 2007-12-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
CN101878203A (zh) | 2007-10-29 | 2010-11-03 | 纳科法尔马有限公司 | 作为抗癌剂的新的4-(四唑-5-基)喹唑啉衍生物 |
AU2008319366B2 (en) * | 2007-10-29 | 2012-03-01 | Amgen Inc. | Benzomorpholine derivatives and methods of use |
WO2009098061A1 (de) | 2008-02-07 | 2009-08-13 | Boehringer Ingelheim International Gmbh | Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
NZ589883A (en) | 2008-05-13 | 2012-06-29 | Astrazeneca Ab | Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline |
JP5539351B2 (ja) | 2008-08-08 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法 |
TWI447108B (zh) | 2009-01-16 | 2014-08-01 | Exelixis Inc | N-(4-{〔6,7雙(甲氧基)喹啉-4-基〕氧基}苯基)-n’-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽及其結晶型 |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
EP2956138B1 (en) | 2013-02-15 | 2022-06-22 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
ES2831625T3 (es) | 2013-02-20 | 2021-06-09 | Kala Pharmaceuticals Inc | Compuestos terapéuticos y sus usos |
MX355330B (es) | 2013-11-01 | 2018-04-16 | Kala Pharmaceuticals Inc | Formas cristalinas de compuestos terapeuticos y sus usos. |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
WO2015077375A1 (en) | 2013-11-20 | 2015-05-28 | Signalchem Lifesciences Corp. | Quinazoline derivatives as tam family kinase inhibitors |
WO2016021742A1 (en) | 2014-08-07 | 2016-02-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds as ep4 receptor antagonists |
JP2019533641A (ja) | 2016-09-08 | 2019-11-21 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物の結晶形態およびその使用 |
WO2018048747A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
EP3509423A4 (en) | 2016-09-08 | 2020-05-13 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
CN108285421A (zh) * | 2018-01-26 | 2018-07-17 | 黑龙江鑫创生物科技开发有限公司 | 一种微通道反应器合成拉帕替尼中间体的方法 |
CN110343090B (zh) * | 2018-04-08 | 2021-06-04 | 威尚(上海)生物医药有限公司 | 喹唑啉衍生物盐型晶型及制备方法和应用 |
CN110357858B (zh) * | 2018-04-09 | 2022-02-18 | 威尚(上海)生物医药有限公司 | 具有穿过血脑屏障能力的5取代二氟哌啶化合物 |
EP3778589B1 (en) * | 2018-04-09 | 2022-05-11 | Weishang (Shanghai) Bio-Pharmaceutical Co., Ltd. | 5-substituted difluoropiperidine compound capable of passing through blood-brain barrier |
FR3080620B1 (fr) * | 2018-04-27 | 2021-11-12 | Univ Paris Sud | Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices |
AR117424A1 (es) * | 2018-05-08 | 2021-08-04 | Dizal Jiangsu Pharmaceutical Co Ltd | Inhibidores de los receptores erbb |
CN109336828B (zh) * | 2018-11-30 | 2022-04-26 | 雅安职业技术学院 | 一种喹唑啉衍生物及其制备方法和应用 |
TWI847289B (zh) * | 2021-09-30 | 2024-07-01 | 大陸商北京賽特明強醫藥科技有限公司 | 喹唑啉類化合物、組合物及其應用 |
CN115894455B (zh) * | 2021-09-30 | 2024-04-19 | 北京赛特明强医药科技有限公司 | 一种喹唑啉类化合物、组合物及其应用 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5538325A (en) * | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
US4335127A (en) * | 1979-01-08 | 1982-06-15 | Janssen Pharmaceutica, N.V. | Piperidinylalkyl quinazoline compounds, composition and method of use |
GB2160201B (en) * | 1984-06-14 | 1988-05-11 | Wyeth John & Brother Ltd | Quinazoline and cinnoline derivatives |
US4921863A (en) * | 1988-02-17 | 1990-05-01 | Eisai Co., Ltd. | Cyclic amine derivatives |
CA1340821C (en) * | 1988-10-06 | 1999-11-16 | Nobuyuki Fukazawa | Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components |
US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
TW321649B (no) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US6046206A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
BR9702049B1 (pt) * | 1996-01-31 | 2010-08-10 | sistema distribuidor contendo dois compartimentos para a dosagem simultánea de duas composições aquosas. | |
GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
DK0912559T3 (da) * | 1996-07-13 | 2003-03-10 | Glaxo Group Ltd | Kondenserede heterocykliske forbindelser som proteintyrosinkinaseinhibitorer |
US6004967A (en) * | 1996-09-13 | 1999-12-21 | Sugen, Inc. | Psoriasis treatment with quinazoline compounds |
CA2282439C (en) * | 1997-03-05 | 2010-05-04 | Sugen, Inc. | Formulations for hydrophobic pharmaceutical agents |
AR012634A1 (es) * | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
US5929080A (en) * | 1997-05-06 | 1999-07-27 | American Cyanamid Company | Method of treating polycystic kidney disease |
US6384223B1 (en) * | 1998-07-30 | 2002-05-07 | American Home Products Corporation | Substituted quinazoline derivatives |
US6297258B1 (en) * | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
AU3281600A (en) * | 1999-02-27 | 2000-09-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transsduction mediated by tyrosine kinases |
US6080747A (en) * | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
UA73993C2 (uk) * | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
US20020082270A1 (en) * | 2000-08-26 | 2002-06-27 | Frank Himmelsbach | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
US6562319B2 (en) * | 2001-03-12 | 2003-05-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy |
WO2002094790A1 (fr) * | 2001-05-23 | 2002-11-28 | Mitsubishi Pharma Corporation | Compose heterocyclique condense et son utilisation medicale |
JP2005512972A (ja) * | 2001-10-12 | 2005-05-12 | アイアールエム エルエルシー | キナーゼ阻害剤足場およびそれらの調製方法 |
MXPA04004219A (es) * | 2001-11-03 | 2004-09-10 | Astrazeneca Ab | Derivados de quinazolina como agentes antitumorales. |
TW200813014A (en) * | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
US6924285B2 (en) * | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
GB0309009D0 (en) * | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
GB0309850D0 (en) * | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
UY28441A1 (es) * | 2003-07-29 | 2005-02-28 | Astrazeneca Ab | Derivados de quinazolina |
GB0317665D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
CN1882573A (zh) * | 2003-09-16 | 2006-12-20 | 阿斯利康(瑞典)有限公司 | 作为酪氨酸激酶抑制剂的喹唑啉衍生物 |
DE602004022180D1 (de) * | 2003-09-16 | 2009-09-03 | Astrazeneca Ab | Chinazolinderivate |
GB0321648D0 (en) * | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
DK1667991T3 (da) * | 2003-09-16 | 2008-08-18 | Astrazeneca Ab | Quinazolinderivater som tyrosinkinaseinhibitorer |
WO2005028470A1 (en) * | 2003-09-19 | 2005-03-31 | Astrazeneca Ab | Quinazoline derivatives |
BRPI0414735A (pt) * | 2003-09-25 | 2006-11-21 | Astrazeneca Ab | derivado de quinazolina, composto, composição farmacêutica, uso de derivado de quinazolina, método para produzir um efeito anti-proliferativo em um animal de sangue quente, e, processo para a preparação de um derivado de quinazolina |
GB0322409D0 (en) * | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
GB0326459D0 (en) * | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
EP1713781B1 (en) * | 2004-02-03 | 2008-11-05 | AstraZeneca AB | Quinazoline derivatives |
CN1993349A (zh) * | 2004-06-04 | 2007-07-04 | 阿斯利康(瑞典)有限公司 | 作为erbb受体酪氨酸激酶的喹唑啉衍生物 |
-
2001
- 2001-11-03 GB GBGB0126433.2A patent/GB0126433D0/en not_active Ceased
-
2002
- 2002-10-31 DE DE60230995T patent/DE60230995D1/de not_active Expired - Lifetime
- 2002-10-31 ES ES02774961T patent/ES2319880T3/es not_active Expired - Lifetime
- 2002-10-31 WO PCT/GB2002/004932 patent/WO2003040109A2/en active Application Filing
- 2002-10-31 EP EP02774961A patent/EP1444211B1/en not_active Expired - Lifetime
- 2002-10-31 US US10/494,388 patent/US20050054662A1/en not_active Abandoned
- 2002-10-31 CA CA002465100A patent/CA2465100A1/en not_active Abandoned
- 2002-10-31 AT AT02774961T patent/ATE421507T1/de not_active IP Right Cessation
- 2002-10-31 HU HU0401994A patent/HUP0401994A2/hu unknown
- 2002-10-31 JP JP2003542155A patent/JP2005511603A/ja not_active Ceased
- 2002-10-31 CN CNA028262824A patent/CN1764651A/zh active Pending
- 2002-10-31 KR KR1020047006735A patent/KR20050042058A/ko not_active Application Discontinuation
- 2002-10-31 IL IL16162002A patent/IL161620A0/xx unknown
- 2002-10-31 BR BR0213843-3A patent/BR0213843A/pt not_active IP Right Cessation
- 2002-10-31 MX MXPA04004220A patent/MXPA04004220A/es unknown
- 2002-10-31 PL PL02369833A patent/PL369833A1/xx not_active Application Discontinuation
- 2002-10-31 RU RU2004116908/04A patent/RU2004116908A/ru not_active Application Discontinuation
- 2002-10-31 NZ NZ532523A patent/NZ532523A/en unknown
- 2002-11-01 TW TW091132368A patent/TW200302221A/zh unknown
- 2002-11-01 AR ARP020104182A patent/AR037193A1/es not_active Application Discontinuation
-
2004
- 2004-04-28 ZA ZA200403200A patent/ZA200403200B/en unknown
- 2004-04-28 ZA ZA200403203A patent/ZA200403203B/en unknown
- 2004-04-30 IS IS7241A patent/IS7241A/is unknown
- 2004-06-02 CO CO04051630A patent/CO5580775A2/es not_active Application Discontinuation
- 2004-06-03 NO NO20042288A patent/NO20042288L/no not_active Application Discontinuation
- 2004-11-08 HK HK04108771.4A patent/HK1065801A1/xx not_active IP Right Cessation
-
2006
- 2006-05-31 US US11/443,395 patent/US20070088044A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20050054662A1 (en) | 2005-03-10 |
ES2319880T3 (es) | 2009-05-14 |
RU2004116908A (ru) | 2005-11-10 |
HUP0401994A2 (hu) | 2005-01-28 |
ZA200403200B (en) | 2005-07-28 |
MXPA04004220A (es) | 2004-09-10 |
ATE421507T1 (de) | 2009-02-15 |
EP1444211B1 (en) | 2009-01-21 |
EP1444211A2 (en) | 2004-08-11 |
PL369833A1 (en) | 2005-05-02 |
NZ532523A (en) | 2007-02-23 |
WO2003040109A3 (en) | 2003-06-26 |
US20070088044A1 (en) | 2007-04-19 |
WO2003040109A2 (en) | 2003-05-15 |
JP2005511603A (ja) | 2005-04-28 |
IS7241A (is) | 2004-04-30 |
ZA200403203B (en) | 2005-07-28 |
CA2465100A1 (en) | 2003-05-15 |
IL161620A0 (en) | 2004-09-27 |
HK1065801A1 (en) | 2005-03-04 |
DE60230995D1 (de) | 2009-03-12 |
TW200302221A (en) | 2003-08-01 |
CN1764651A (zh) | 2006-04-26 |
KR20050042058A (ko) | 2005-05-04 |
GB0126433D0 (en) | 2002-01-02 |
AR037193A1 (es) | 2004-10-27 |
CO5580775A2 (es) | 2005-11-30 |
BR0213843A (pt) | 2004-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20042279L (no) | Kinazolinderivater som antitumormidler | |
NO20042288L (no) | Kinazolinderivater som antitumormidler | |
NO20032531D0 (no) | Tetralon-derivater som antitumormidler | |
ATE319451T1 (de) | Tetrahydrochinolin-derivate | |
DK1419152T3 (da) | HIV-hæmmende pyrimidin-derivater | |
ATE312827T1 (de) | 3-substituierte-4-pyrimidonderivate | |
DK1487806T3 (da) | 4-anilin-quinazolinderivater som antiproliferative midler | |
NO20035366L (no) | Benzoylsulfonamider og sulfonylbenzamidiner for anvendelse som antitumormidler | |
NO20034439L (no) | Benzamidinderivater | |
NO20031447L (no) | Paclitaxel-basert antitumor-formulering | |
DK1847539T3 (da) | Quinazolin-derivater | |
DK1414440T3 (da) | N-phenylpyrrolguanidinderivater som melanocortinreceptorligander | |
DK1385825T3 (da) | Substituerede 2-pyridincyclohexan-1,4-diaminderivater | |
DK1633365T3 (da) | Makrocykliske quinazolinderivater som antiproliferative midler | |
IS7328A (is) | Útskiptar kínasólínafleiður sem hemlar gegn árórakínösum | |
NO20033593L (no) | Kinazoliner som MMP-13 inhibitorer | |
NO20035634D0 (no) | Diamin-derivater | |
DK1456206T3 (da) | Azaindolylalkylaminderivater som 5-hydroxytryptamin-6-ligander | |
DK1455779T3 (da) | Indolylalkylaminderivater som 5-hydroxytryptamin-6-ligander | |
ATE459598T1 (de) | Sulfonamidderivate | |
EE200300447A (et) | Asendatud bensofuraan-2-karboksamiidide derivaadid | |
NO20034647L (no) | Hydroksyclylalkoksy-, alkyloksy- og -alkylaminobenzazol- derivater som 5-hydroksytryptamin-6-ligander | |
NO20035573D0 (no) | Kinazolinderivater | |
DE60223031D1 (de) | Arylpiperazin gebundene tetrahydroindolonderivate | |
NO20033234L (no) | Karotenoider som antihypertensjonsmidler |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |